The DOI matches its OpenAlex record; 57 of the 57 references it cites were found in a registry or an index.
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Open accessAbstract
In type 2 diabetes, chronic hyperglycemia is suggested to be detrimental to pancreatic beta cells, causing impaired insulin secretion. IL-1beta is a proinflammatory cytokine acting during the autoimmune process of type 1 diabetes. IL-1beta inhibits beta cell function and promotes Fas-triggered apoptosis in part by activating the transcription factor NF-kappaB. Recently, we have shown that increased glucose concentrations also induce Fas expression and beta cell apoptosis in human islets. The aim of the present study was to test the hypothesis that IL-1beta may mediate the deleterious effects of high glucose on human beta cells. In vitro exposure of islets from nondiabetic organ donors to high glucose levels resulted in increased production and release of IL-1beta, followed by NF-kappaB activation, Fas upregulation, DNA fragmentation, and impaired beta cell function. The IL-1 receptor antagonist protected cultured human islets from these deleterious effects. beta cells themselves were identified as the islet cellular source of glucose-induced IL-1beta. In vivo, IL-1beta-producing beta cells were observed in pancreatic sections of type 2 diabetic patients but not in nondiabetic control subjects. Similarly, IL-1beta was induced in beta cells of the gerbil Psammomys obesus during development of diabetes. Treatment of the animals with phlorizin normalized plasma glucose and prevented beta cell expression of IL-1beta. These findings implicate an inflammatory process in the pathogenesis of glucotoxicity in type 2 diabetes and identify the IL-1beta/NF-kappaB pathway as a target to preserve beta cell mass and function in this condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
Automated Method for Isolation of Human Pancreatic Islets
Ricordi, C., Lacy, P. E., Finke, E. H., Olack, B. J., & Scharp, D. W. (1988) · Diabetes · doi:10.2337/diab.37.4.413 · Cited by 1,310
How NF-κB is activated: the role of the IκB kinase (IKK) complex
Karin, M. (1999) · Oncogene · doi:10.1038/sj.onc.1203219 · Cited by 1,156
β-Cell death during progression to diabetes
Mathis, D., Vence, L., & Benoist, C. (2001) · Nature · doi:10.1038/414792a · Cited by 884
Rossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 770
The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes
Wilkin, T. J. (2001) · Diabetologia · doi:10.1007/s001250100548 · Cited by 623
Distinct Effects of Saturated and Monounsaturated Fatty Acids on β-Cell Turnover and Function
Maedler, K., Spinas, G. A., Dyntar, D., Moritz, W., Kaiser, N., & Donath, M. Y. (2001) · Diabetes · doi:10.2337/diabetes.50.1.69 · Cited by 552
Self-citationThe role of interleukin-1 in the pathogenesis of IDDM
Mandrup-Poulsen, T. (1996) · Diabetologia · doi:10.1007/bf00400649 · Cited by 543
Cytotoxicity of Human p I 7 Interleukin-1 for Pancreatic Islets of Langerhans
Bendtzen, K., Mandrup-Poulsen, T., Nerup, J., Nielsen, J. H., Dinarello, C. A., & Svenson, M. (1986) · Science · doi:10.1126/science.3086977 · Cited by 529
Unger, R. H., & Grundy, S. (1985) · Diabetologia · doi:10.1007/bf00273856 · Cited by 452
Research works printed but not linked: 10
- 10.2337/diabetes.38.12.1501 · DOI
- 10.2337/diabetes.43.9.1085 · DOI
- 10.2337/diabetes.50.8.1741 · doi:10.2337/diabetes.50.8.1741
- 10.2337/diabetes.46.7.1120 · DOI
- 10.2337/diabetes.37.4.413 · DOI
- Kaiser, 1991, Endocrinology, 129, 2067, 10.1210/endo-129-4-2067 · DOI
- 10.2337/diabetes.41.4.548 · DOI
- Lacy, 1991, Am J Pathol, 138, 1183
- Lacy, 1994, Mt Sinai J Med, 61, 170
- 10.1210/en.135.2.610 · doi:10.1210/en.135.2.610
Cited by
Inflammasomes: mechanism of action, role in disease, and therapeutics
Guo, H., Callaway, J. B., & Ting, J. P.-Y. (2015) · Nature Medicine · doi:10.1038/nm.3893 · Cited by 3,340
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Self-citationFrom endoplasmic-reticulum stress to the inflammatory response
Zhang, K., & Kaufman, R. J. (2008) · Nature · doi:10.1038/nature07203 · Cited by 2,010
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
The cellular and signaling networks linking the immune system and metabolism in disease
Osborn, O., & Olefsky, J. M. (2012) · Nature Medicine · doi:10.1038/nm.2627 · Cited by 1,551
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330
Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes
Zatterale, F., Longo, M., Naderi, J., Raciti, G. A., Desiderio, A., Miele, C., & Beguinot, F. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01607 · Cited by 1,180
Oxidative stress in obesity: A critical component in human diseases
Marseglia, L., Manti, S., D’Angelo, G., Nicotera, A., Parisi, E., Di Rosa, G., Gitto, E., & Arrigo, T. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010378 · Cited by 933
Historical insights into cytokines
Dinarello, C. A. (2007) · European Journal of Immunology · doi:10.1002/eji.200737772 · Cited by 926
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161521 · Cited by 799
Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., & Rouis, M. (2015) · Redox Biology · doi:10.1016/j.redox.2015.01.008 · Cited by 732
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
NF-κB: At the Borders of Autoimmunity and Inflammation
Barnabei, L., Laplantine, E., Mbongo, W., Rieux-Laucat, F., & Weil, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716469 · Cited by 630
The role of interleukin-1 in general pathology
Kaneko, N., Kurata, M., Yamamoto, T., Morikawa, S., & Masumoto, J. (2019) · Inflammation and Regeneration · doi:10.1186/s41232-019-0101-5 · Cited by 617
The inflammation highway: metabolism accelerates inflammatory traffic in obesity
Johnson, A. R., Justin Milner, J., & Makowski, L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01151.x · Cited by 603
Defining and Characterizing the Progression of Type 2 Diabetes
Fonseca, V. A. (2009) · Diabetes Care · doi:10.2337/dc09-s301 · Cited by 573
Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition
Hameed, I., Masoodi, S. R., Mir, S. A., Nabi, M., Ghazanfar, K., & Ganai, B. A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i4.598 · Cited by 506
Foundations of Immunometabolism and Implications for Metabolic Health and Disease
Hotamisligil, G. S. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.009 · Cited by 505
Meier, J. J., Bhushan, A., Butler, A. E., Rizza, R. A., & Butler, P. C. (2005) · Diabetologia · doi:10.1007/s00125-005-1949-2 · Cited by 493
Autoinflammatory Disease Reloaded: A Clinical Perspective
Kastner, D. L., Aksentijevich, I., & Goldbach-Mansky, R. (2010) · Cell · doi:10.1016/j.cell.2010.03.002 · Cited by 487
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
Mechanisms of β-Cell Death in Type 2 Diabetes
Donath, M. Y., Ehses, J. A., Maedler, K., Schumann, D. M., Ellingsgaard, H., Eppler, E., & Reinecke, M. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s108 · Cited by 444
Self-citationAn Integrated View of Immunometabolism
Lee, Y. S., Wollam, J., & Olefsky, J. M. (2018) · Cell · doi:10.1016/j.cell.2017.12.025 · Cited by 436
Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications
Donath, M. Y., & Halban, P. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1336-4 · Cited by 430
Self-citationInflammatory mediators and islet ?-cell failure: a link between type 1 and type 2 diabetes
Donath, M. Y., St�rling, J., Maedler, K., & Mandrup-Poulsen, T. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0450-y · Cited by 422
Self-citationSustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009) · Diabetes Care · doi:10.2337/dc09-0533 · Cited by 401
Self-citationTargeting innate immune mediators in type 1 and type 2 diabetes
Donath, M. Y., Dinarello, C. A., & Mandrup-Poulsen, T. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0213-9 · Cited by 416
Self-citationAn immune origin of type 2 diabetes?
Kolb, H., & Mandrup-Poulsen, T. (2005) · Diabetologia · doi:10.1007/s00125-005-1764-9 · Cited by 394
Dror, E., Dalmas, E., Meier, D. T., Wueest, S., Thévenet, J., Thienel, C., Timper, K., Nordmann, T. M., Traub, S., Schulze, F., et al. (2017) · Nature Immunology · doi:10.1038/ni.3659 · Cited by 394
Self-citationThe role of macrophages in obesity-associated islet inflammation and β-cell abnormalities
Ying, W., Fu, W., Lee, Y. S., & Olefsky, J. M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0286-3 · Cited by 391
Jourdan, T., Godlewski, G., Cinar, R., Bertola, A., Szanda, G., Liu, J., Tam, J., Han, T., Mukhopadhyay, B., Skarulis, M. C., et al. (2013) · Nature Medicine · doi:10.1038/nm.3265 · Cited by 388
Keane, K. N., Cruzat, V. F., Carlessi, R., de Bittencourt, P. I. H., & Newsholme, P. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/181643 · Cited by 383
Islet inflammation in type 2 diabetes and physiology
Eguchi, K., & Nagai, R. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88877 · Cited by 361
Moran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60023-9 · Cited by 356
Self-citationPancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress
Dludla, P. V., Mabhida, S. E., Ziqubu, K., Nkambule, B. B., Mazibuko-Mbeje, S. E., Hanser, S., Basson, A. K., Pheiffer, C., & Kengne, A. P. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i3.130 · Cited by 344
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308
The IL-1β phenomena in neuroinflammatory diseases
Mendiola, A. S., & Cardona, A. E. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1732-9 · Cited by 303
Benner, C., van der Meulen, T., Cacéres, E., Tigyi, K., Donaldson, C. J., & Huising, M. O. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-620 · Cited by 302
Islet β cell mass in diabetes and how it relates to function, birth, and death
Weir, G. C., & Bonner‐Weir, S. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12031 · Cited by 296
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
Sone, H., & Kagawa, Y. (2005) · Diabetologia · doi:10.1007/s00125-004-1605-2 · Cited by 286
Cytokines and abnormal glucose and lipid metabolism
Shi, J., Fan, J., Su, Q., & Yang, Z. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00703 · Cited by 282
Level of IL-6, TNF, and IL-1β and age-related diseases: a systematic review and meta-analysis
Tylutka, A., Walas, Ł., & Zembron-Lacny, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1330386 · Cited by 262
Ballak, D. B., Stienstra, R., Tack, C. J., Dinarello, C. A., & van Diepen, J. A. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.005 · Cited by 255
Alonso, L. C., Yokoe, T., Zhang, P., Scott, D. K., Kim, S. K., O'Donnell, C. P., & Garcia-Ocaña, A. (2007) · Diabetes · doi:10.2337/db06-1513 · Cited by 252
NALP Inflammasomes: a central role in innate immunity
Martinon, F., Gaide, O., Pétrilli, V., Mayor, A., & Tschopp, J. (2007) · Seminars in Immunopathology · doi:10.1007/s00281-007-0079-y · Cited by 218
Diabetes and beta cell function: from mechanisms to evaluation and clinical implications
Cernea, S., & Dobreanu, M. (2013) · Biochemia Medica · doi:10.11613/bm.2013.033 · Cited by 203
The Inflammasome in Atherosclerosis and Type 2 Diabetes
Masters, S. L., Latz, E., & O’Neill, L. A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001902 · Cited by 169
Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity
Osborn, O., Brownell, S. E., Sanchez-Alavez, M., Salomon, D., Gram, H., & Bartfai, T. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.004 · Cited by 160
Aging Correlates With Decreased β-Cell Proliferative Capacity and Enhanced Sensitivity to Apoptosis
Maedler, K., Schumann, D. M., Schulthess, F., Oberholzer, J., Bosco, D., Berney, T., & Donath, M. Y. (2006) · Diabetes · doi:10.2337/db05-1586 · Cited by 158
Self-citationRetractedGerst, F., Wagner, R., Kaiser, G., Panse, M., Heni, M., Machann, J., Bongers, M. N., Sartorius, T., Sipos, B., Fend, F., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4385-1 · Cited by 151
Carstensen, M., Herder, C., Kivimäki, M., Jokela, M., Roden, M., Shipley, M. J., Witte, D. R., Brunner, E. J., & Tabák, A. G. (2010) · Diabetes · doi:10.2337/db09-1199 · Cited by 137
Role of Cellular Senescence in Type II Diabetes
Narasimhan, A., Flores, R. R., Robbins, P. D., & Niedernhofer, L. J. (2021) · Endocrinology · doi:10.1210/endocr/bqab136 · Cited by 133
Somm, E., Cettour-Rose, P., Asensio, C., Charollais, A., Klein, M., Theander-Carrillo, C., Juge-Aubry, C. E., Dayer, J. M., Nicklin, M. J. H., Meda, P., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0046-x · Cited by 111
Autoimmune Aspects of Type 2 Diabetes Mellitus - A Mini-Review
Itariu, B. K., & Stulnig, T. M. (2014) · Gerontology · doi:10.1159/000356747 · Cited by 107
Pancreatic islet inflammation in type 2 diabetes: From α and β cell compensation to dysfunction
Ehses, J. A., Ellingsgaard, H., Böni-Schnetzler, M., & Donath, M. Y. (2009) · Archives of Physiology and Biochemistry · doi:10.1080/13813450903025879 · Cited by 97
Self-citationβ-Cell deterioration during diabetes: what’s in the gun?
Robertson, R. P. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.05.004 · Cited by 93
Glucolipotoxicity in Pancreatic β-Cells
Kim, J.-W., & Yoon, K.-H. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.5.444 · Cited by 82
β-Cell failure in type 2 diabetes
Leibowitz, G., Kaiser, N., & Cerasi, E. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00094.x · Cited by 78
Self-citationβ‐cell mass in people with type 2 diabetes
Cho, J., Kim, J., Shin, J., Shin, J., & Yoon, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00072.x · Cited by 69
Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments
Li, G., Wan, Y., Jiao, A., Jiang, K., Cui, G., Tang, J., Yu, S., Hu, Z., Zhao, S., Yi, Z., et al. (2025) · Med Research · doi:10.1002/mdr2.70007 · Cited by 63
Farnsworth, N. L., Walter, R. L., Hemmati, A., Westacott, M. J., & Benninger, R. K. P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679506 · Cited by 48
Herder, C., Nuotio, M.-L., Shah, S., Blankenberg, S., Brunner, E. J., Carstensen, M., Gieger, C., Grallert, H., Jula, A., Kähönen, M., et al. (2014) · Diabetes · doi:10.2337/db14-0731 · Cited by 46
Knudsen, S. H., & Pedersen, B. K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0642-1 · Cited by 41
Agarwal, P., Brar, N., Morriseau, T. S., Kereliuk, S. M., Fonseca, M. A., Cole, L. K., Jha, A., Xiang, B., Hunt, K. L., Seshadri, N., et al. (2019) · Endocrinology · doi:10.1210/en.2019-00232 · Cited by 34
González-Álvarez, M. E., Riquelme-Aguado, V., González-Pérez, Á., Murillo-Llergo, R., Manjón-Olmedillas, M., Turroni, S., Rossettini, G., & Villafañe, J. H. (2024) · Cells · doi:10.3390/cells13201719 · Cited by 20
Metadata
- Authors
- Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller‐Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-09-15
- Volume
- 110
- Issue
- 6
- Pages
- 851-860
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4240175730
- Cited by
- 363
- References
- 57
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.